Anti-Inflammatory Diet Home Page...
 
Web Level1Diet.com
Subscribe to Anti-Inflammatory Diet RSS feeds...
Subscribe
Free Anti-inflammatory diet summary... Anti-inflammation diet weight loss story... 
Home Foods to Eat Foods to Avoid Exercise Supplements Weight Loss News Diabetes News Your Concerns Archived Reports

Bookmark Us: Yahoo Del.icio.us Simpy Technorati Email a friend Print

COPD
Health Information Search Results

Matching Summaries of Recent
Peer Reviewed Scientific Research Reports.


Refine Your Search:

All Words Any Words
Search Again By Year -- Simply add a space, then the year you want to your search term.
 


 << Prev 20  Showing 1 to 17 of 17 Matches Next 20 >>



1. Measures to improve knowledge and self-care among patients with COPD: A UK general practice audit.
Match Strength: 8.211

The Parchmore Partnership, London, audited 11 evidence-based criteria relating to patient knowledge and COPD morbidity during December 2004 to March 2005 using questionnaires and practice records. 32 patients with moderate to severe COPD participated, and during the project they received information and extra care. Patient knowledge and clinical indicators showed significant improvements ... Read More »
» Published in Prim Care Respir J. 2006 Oct;15(5):307-9. Epub 2006 Sep 14.

2. Relationship between airway colonization, inflammation and exacerbation frequency in COPD.
Match Strength: 8.138

RATIONALE: To evaluate bacterial colonization and the airway inflammatory response, and its relationship to the frequency of exacerbation in patients with stable chronic obstructive pulmonary disease (COPD). METHODS: Quantitative bacteriologic cultures, neutrophil elastase, myeloperoxidase (MPO), tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 were measured in bronchoalveoler lavage (BAL) in 39 patients with stable COPD [19 with frequent exacerbation (3/year), and 20 with infrequent] and in 18 healthy controls (10 smokers and 8 non-smokers). RESULTS: BAL revealed the ... Read More »
» Published in Respir Med. 2006 Sep 23;

3. The prevalence of venous insufficiency in patients with chronic obstructive pulmonary disease evaluated by color duplex ultrasonography.
Match Strength: 8.070

OBJECTIVES: We hypothesized that in patients with chronic obstructive pulmonary disease (COPD) some extrapulmonary effects such as increase in intra-abdominal and intra-thoracic pressures, presence of cor pulmonale and pulmonary artery hypertension could cause venous insufficiency (VI) in the lower limbs. Our aim in this study was to assess the prevalence of VI in patients with COPD in comparison with healthy controls. METHODS: Thirty-nine male patients with COPD and 36 healthy male controls were evaluated for VI. All the participants were in the same age group and their smoking intensities ... Read More »
» Published in Wien Klin Wochenschr. 2006 Sep;118(17-18):549-53.

4. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm.
Match Strength: 7.851

RATIONALE: The few prospective studies aimed at assessing the incidence of chronic obstructive pulmonary disease (COPD) in relation to the presence of chronic cough/phlegm have produced contrasting results. OBJECTIVES: To assess the incidence of COPD in a cohort of young adults and to test whether chronic cough/phlegm and dyspnea are independent predictors of COPD. METHODS: An international cohort of 5,002 subjects without asthma (ages 20-44 yr) with normal lung function (FEV(1)/FVC ratio >/= 70%) from 12 countries was followed from 1991-2002 in the frame of the European Community ... Read More »
» Published in Am J Respir Crit Care Med. 2007 Jan 1;175(1):32-9. Epub 2006 Sep 28.

5. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure.
Match Strength: 7.601

OBJECTIVE: To determine the prevalence of confirmatory use of spirometry in patients admitted to a tertiary-care facility with the diagnosis of chronic obstructive pulmonary disease (COPD), including those with respiratory failure, and compare that to the use of confirmatory 2-dimensional echocardiography (2-D echo) in patients admitted with the diagnosis of congestive heart failure (CHF), to determine preferential confirmatory testing practices. SETTING: Academic tertiary-care hospital. METHODS: A 6-month retrospective review of charts of patients with a primary or secondary discharge ... Read More »
» Published in Respir Care. 2006 Oct;51(10):1120-4. Comment in: Respir Care. 2006 Oct;51(10):1116-7.

6. Trends and ethnic differences in COPD hospitalization and mortality in Singapore.
Match Strength: 7.422

STUDY OBJECTIVE: COPD mortality alone among major causes of diseases continues to rise in most countries worldwide. We examine trends, and gender and ethnic differences in COPD hospitalization and mortality in Singapore from 1991 to 1998, and examine possible explanations. DESIGN: Analysis of population-based health administrative data. SETTING: Multi-ethnic (Chinese, Malay and Indian) population of Singapore (3 million population). METHOD: Data on hospitalizations and deaths due to COPD as the underlying cause (ICD codes 491, 492, 496), extracted from national databases, were used to ... Read More »
» Published in COPD. 2004 Apr;1(1):5-11.

7. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease.
Match Strength: 6.917

Severe exacerbations of chronic obstructive pulmonary disease (COPD) are morbid events with slow recovery periods. They consume substantial healthcare resources, and they may cause a more rapid reduction in lung function over time. Quality of life (QOL) deteriorates in patients who experience exacerbations, and the more frequent the exacerbations, the more rapid the decline in QOL. Hospitalizations due to exacerbations account for up to 70% of the cost of medical care for patients with COPD. Patients with more severe COPD have more hospitalizations compared with those with less severe disease. ... Read More »
» Published in Am J Med. 2006 Oct;119(10 Suppl 1):38-45.

8. The comparison of different dyspnoea scales in patients with COPD.
Match Strength: 6.876

OBJECTIVES: (i) To compare the relationship between different dyspnoea scales and physical and clinical parameters of patients with chronic obstructive pulmonary disease (COPD); and (ii) to determine the most suitable scale among these scales for this patient group. METHODS: Forty patients with COPD [mean 1st second forced expiratory volume (FEV(1)), 49.16 +/- 2.33% predicted], aged 53-85 participated in this study. The severity of dyspnoea was assessed with different five scales [Modified Borg Scale (MBS), Visual Analogue Scale (VAS), Medical Research Council Dyspnoea Scale (MRCS), Baseline ... Read More »
» Published in J Eval Clin Pract. 2006 Oct;12(5):532-8.

9. Comparison of oral and depot intra-muscular steroids in assessing steroid-responsiveness in COPD.
Match Strength: 5.748

Non-compliance or euphoria may limit the usefulness of prednisolone tablets in assessing steroid-responsiveness in chronic obstructive pulmonary disease (COPD). Depot intra-muscular methyl-prednisolone (imMP), producing a plateau steroid effect over two weeks, may be more reliable. Following two weeks of placebo, twenty-seven COPD patients (mean FEV 1 43% predicted) participated in a two-week randomised, double-blind, placebo-controlled, parallel-design trial taking either 120 mg imMP with placebo tablets or placebo injection with prednisolone 30 mg daily. After each period, post ... Read More »
» Published in COPD. 2004 Apr;1(1):33-40.

10. A community model of group therapy for the older patients with chronic obstructive pulmonary disease: a pilot study.
Match Strength: 5.718

OBJECTIVE: A community-based programme for chronic obstructive pulmonary disease (COPD) patients in group sessions is designed, and the feasibility, acceptability and physical and psychosocial outcomes evaluated. METHODS: Patients with COPD discharged from hospital, or those attending specialist outpatient clinic, with a history of hospital admission owing to COPD in the preceding 12 months were recruited. Those who had malignancy or were housebound were excluded. Group sessions were arranged once a week in a Community Centre, and consisted of two hourly sessions. The components of each ... Read More »
» Published in J Eval Clin Pract. 2006 Oct;12(5):523-31.

11. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions.
Match Strength: 5.594

PURPOSE: To compare refill adherence data based on two different methods of data capturing, that is, manually collected repeat prescriptions and a pharmacy record database. METHODS: The study comprised a comparison of adherence data from manually collected repeat prescriptions of asthma and chronic obstructive pulmonary disease (COPD) drugs with fixed dosages dispensed in 2002 and the corresponding data from a pharmacy record database. Data were collected in the county of Jamtland in Sweden. Refill adherence was calculated for the different collection methods. RESULTS: Data from 285 manually ... Read More »
» Published in Pharmacoepidemiol Drug Saf. 2006 Sep 28;

12. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
Match Strength: 5.456

The aim of this study was to determine whether combined inhaled corticosteroids and long-acting beta(2) agonists can suppress eosinophilic inflammation in chronic dostructive plumonary disease (COPD) and to investigate the association between the level of eosinophilia and the degree of bronchodilator reversibility. Sixty-two patients with stable COPD (forced expiratory volume in 1 [FEV(1)] of 30%-70% predicted before bronchodilation) were enrolled from our outpatient clinic. Patients received inhaled fluticasone (100 microg)/salmeterol (50 microg) twice daily for two months. Lung function ... Read More »
» Published in Lung. 2006 Jul-Aug;184(4):217-22.

13. Single dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary disease.
Match Strength: 5.371

The aim of this study was to evaluate the effect of a single dose of tiotropium on the exercise capacity of stable chronic obstructive pulmonary disease (COPD) patients. The study was a randomized, placebo-controlled, double-blind, cross-over study. Forty-four stable COPD patients with moderate to severe airway obstruction were selected according to the GOLD criteria. The regular anticholinergic therapies of the patients were interrupted one week before the test. In the morning hours of the first day, half the group was given one capsule (18 mcg) of tiotropium and the other half was given ... Read More »
» Published in Lung. 2006 Jul-Aug;184(4):201-4.

14. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Match Strength: 5.321

OBJECTIVE: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor. DATA SOURCES: Literature was accessed through MEDLINE (1966-May 2006), Current Contents Clinical Medicine (1998-May 2006), and The Cochrane Library Database (1st quarter 2006) using the terms cilomilast, Ariflo, and SB 207 499. Reference lists from retrieved articles and information from the manufacturer were manually reviewed. STUDY SELECTION AND DATA EXTRACTION: All clinical trials evaluating ... Read More »
» Published in Ann Pharmacother. 2006 Oct;40(10):1822-8. Epub 2006 Sep 19.

15. Characterization of igaB, a second immunoglobulin A1 protease gene in nontypeable Haemophilus influenzae.
Match Strength: 4.069

Nontypeable Haemophilus influenzae is an important respiratory pathogen, causing otitis media in children and lower respiratory tract infection in adults with chronic obstructive pulmonary disease (COPD). Immunoglobulin A1 (IgA1) protease is a well-described protein and potential virulence factor in this organism as well as other respiratory pathogens. IgA1 proteases cleave human IgA1, are involved in invasion, and display immunomodulatory effects. We have identified a second IgA1 protease gene, igaB, in H. influenzae that is present in addition to the previously described IgA1 protease gene, ... Read More »
» Published in Infect Immun. 2006 Oct;74(10):5860-70.

16. Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol.
Match Strength: 3.039

The Montreal Protocol on Substances that Deplete the Ozone Layer has led to rapid reductions in the use of ozone-depleting substances worldwide. However, the Protocol provides for "essential use exemptions" (EUEs) if there are no "technically and economically feasible" alternatives. An application that might qualify as an "essential use" is CFC-powered medical metered-dose inhalers (MDIs) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and the US and other nations have applied for exemptions in this case. One concern is that exemptions are necessary to ensure ... Read More »
» Published in J Environ Manage. 2006 Sep 16;

17. Gastrointestinal-related complications after major lung surgery.
Match Strength: 3.020

Numerous factors increase the risk for GI complications in patients undergoing lung resection. It seems that the more debilitated the patient and the more extensive the COPD, the higher the risk. The most commonly reported cause of mortality after lung surgery is multi-organ failure accompanying respiratory failure. The trigger site for multi-system failure is often the GI system. Some risk factors cannot be altered, such as diabetes and the cardiovascular effects of long-term smoking. Other factors, such as steroid dose, anemia, hypoxia, narcotics, and other medications, can be modified. In ... Read More »
» Published in Thorac Surg Clin. 2006 Aug;16(3):299-302.

 << Prev 20  Showing results 1 to 17 of 17 Next 20 >>




* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.



spacer spacer
spacer
Level1Diet.com foods to eat...
   


DO YOU KNOW ?
Over 1,532 new health studies are published every day ― 559,288 per year. Join our weekly update program to stay informed...
spacer

spacer
» About Health Updates


spacer

HAVE WE
HELPED YOU?

Donate $5 or $10
to help us promote
anti-inflammatory health.


spacer
Bigger Font Size Smaller Font Size Left Align Justify Align Right Align Bookmark This Page
spacer
Search 3.1 Million
Health Studies


» List of 4,000+ Diseases
spacer
   

spacer




Subscribe to
Level1Diet.com
Health Reports


Add to Google Reader or Homepage
Subscribe in NewsGator Online
Subscribe in Bloglines
Add to Excite MIX
Add to netvibes
Add to fwicki
Add to My AOL
Add to The Free Dictionary



About Us Contact Us Privacy Free Newsletter Health FAQs Terms of Use

 Subscribe in a reader

© 2010 Level1Diet.com, All Rights Reserved.     Contact:

Replace omega-6 vegetable oils with omega-9 olive oil... Eat oily fish like tuna, sardines, anchovy, salmon, herring... Beans, lentils, peas add fiber... Nine or more 3-ounce servings of fruits or vegetables per day...